The cGAS-STING pathway drives neuroinflammation in ALS through aberrant cytoplasmic mitochondrial DNA recognition, but therapeutic intervention may be more effectively achieved by targeting the downstream kinase TBK1 rather than STING itself. Following STING activation by cGAMP, the pathway's inflammatory output critically depends on TBK1 (TANK-binding kinase 1), a 729-amino acid serine/threonine kinase that serves as the obligate signal transducer for both type I interferon and pro-inflammatory
This hypothesis proposes that TBK1 loss-of-function mutations initiate a pathological cascade where microglia become locked in a senescent state, secreting MMP-9 via the senescence-associated secretory phenotype (SASP), which then generates pathological TDP-43 C-terminal fragments that propagate ALS pathology. The mechanism begins with TBK1 haploinsufficiency disrupting normal microglial homeostasis through impaired NF-κB/IRF3 signaling and defective autophagy, forcing microglia into a senescent
Convergent vs Divergent Predictions
This summary checks where the selected hypotheses point toward the same target or mechanism, and where they pull in opposite directions.
TBK1AutophagyNeuroinflammation
Convergent signals
TBK1 recurs across 2 selected hypotheses with aligned directionality in autophagy, neuroinflammation.
Divergent signals
No direct polarity conflicts detected among the selected hypotheses.
Verdict Summary
8/11
dimensions won
TBK1 Inhibitors as ALS Therapeutics: Tar
1/11
dimensions won
TBK1 Loss Drives Microglial Senescence-S
Radar Chart — 10 Dimensions
Score Comparison Bars
Mechanistic
0.72
0.50
Evidence
0.33
0.00
Novelty
0.00
0.00
Feasibility
0.00
0.00
Impact
0.00
0.00
Druggability
0.85
0.50
Safety
0.58
0.50
Competition
0.70
0.50
Data
0.72
0.50
Reproducible
0.75
0.50
KG Connect
0.50
0.50
Score Breakdown
Dimension
TBK1 Inhibitors as ALS Therape
TBK1 Loss Drives Microglial Se
Mechanistic
0.720
0.500
Evidence
0.325
0.000
Novelty
0.000
0.000
Feasibility
0.000
0.000
Impact
0.000
0.000
Druggability
0.850
0.500
Safety
0.580
0.500
Competition
0.700
0.500
Data
0.720
0.500
Reproducible
0.750
0.500
KG Connect
0.500
0.500
Evidence
TBK1 Inhibitors as ALS Therapeutics: Targeting Downstream ST
No evidence citations yet
TBK1 Loss Drives Microglial Senescence-SASP to Generate MMP-
No evidence citations yet
Debate Excerpts
TBK1 Inhibitors as ALS Therapeutics: Targeting Dow
4 rounds · quality: 0.73
Theorist
# Therapeutic Hypotheses: TDP-43/cGAS/STING in Neurodegeneration
## Hypothesis 1: Chronic cGAS/STING Hyperactivation Drives Progressive Neurodegeneration Through Sustained Type I Interferon Signaling...
Skeptic
# Critical Evaluation of TDP-43/cGAS/STING Hypotheses in Neurodegeneration
---
## Hypothesis 1: Chronic cGAS/STING Hyperactivation via Sustained Type I IFN Signaling
### Weak Links
- **Unproven chr...
Domain Expert
# Feasibility Assessment: TDP-43/cGAS/STING Therapeutic Hypotheses in Neurodegeneration
## Executive Summary
The source paper (Yu et al., Cell 2020) establishes a credible mechanistic link between T...
Synthesizer
{
"ranked_hypotheses": [
{
"title": "STING Antagonists as ALS Therapeutics: Drug Repurposing",
"description": "Existing STING antagonists (H-151, SN-011, Compound 18) developed for a...
TBK1 Loss Drives Microglial Senescence-SASP to Gen
6 rounds · quality: 0.75
Theorist
# Novel Therapeutic Hypotheses: Microglial Senescence in ALS
*Generated from systematic analysis of provided literature and cross-disciplinary synthesis*
---
## Hypothesis 1: TBK1-Deficiency Drives...